3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
PD-1/L1
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...
Antengene and MSD Collaborate on Global Clinical Study for ATG-037
China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...
CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...
Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...
Aosaikang Receives FDA Approval for ASKG915 Clinical Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...
CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...
Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma
China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...
Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...
Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial
China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...